Kalytera Therapeutics, Inc.

09:50 AM EST - Kalytera Therapeutics, Inc. : Announced that it has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been filed in the U.S. and other jurisdictions, and Kalytera has obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd., an Israeli-based pharmaceutical discovery company focused on cannabinoid-based therapeutics for the treatment of human disease. Kalytera Therapeutics, Inc. shares V.KALY are trading up $0.055 at $0.38.